These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34421799)

  • 1. Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease.
    de Aquino CH
    Front Neurol; 2021; 12():694329. PubMed ID: 34421799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field.
    Smedinga M; Darweesh SKL; Bloem BR; Post B; Richard E
    J Neurol; 2021 Feb; 268(2):724-733. PubMed ID: 32809153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prodromal Parkinson's disease: hype or hope for disease-modification trials?
    Mahlknecht P; Marini K; Werkmann M; Poewe W; Seppi K
    Transl Neurodegener; 2022 Feb; 11(1):11. PubMed ID: 35184752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases.
    Seifan A; Ganzer CA; Ryon K; Lin M; Mahmudur R; Adolfo H; Shih C; Jacobs AR; Greenwald M; Isaacson RS
    Curr Aging Sci; 2019; 11(4):242-249. PubMed ID: 30845903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
    Parnetti L; Eusebi P; Lleó A
    Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.
    Lim NS; Swanson CR; Cherng HR; Unger TL; Xie SX; Weintraub D; Marek K; Stern MB; Siderowf A; ; ; Trojanowski JQ; Chen-Plotkin AS
    Ann Clin Transl Neurol; 2016 May; 3(5):346-55. PubMed ID: 27231704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Xiang S; Ji JL; Li S; Cao XP; Xu W; Tan L; Tan CC
    Front Aging Neurosci; 2022; 14():730036. PubMed ID: 35185522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.
    Parnetti L; Chipi E; Salvadori N; D'Andrea K; Eusebi P
    Alzheimers Res Ther; 2019 Jan; 11(1):7. PubMed ID: 30646955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in treating Parkinson's disease.
    Oertel WH
    F1000Res; 2017; 6():260. PubMed ID: 28357055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.
    Lista S; Dubois B; Hampel H
    J Nutr Health Aging; 2015 Feb; 19(2):154-63. PubMed ID: 25651440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodromal dementia with Lewy bodies.
    Fujishiro H; Nakamura S; Sato K; Iseki E
    Geriatr Gerontol Int; 2015 Jul; 15(7):817-26. PubMed ID: 25690399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
    Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
    Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural regeneration therapies for Alzheimer's and Parkinson's disease-related disorders.
    Reddy AP; Ravichandran J; Carkaci-Salli N
    Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165506. PubMed ID: 31276770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep Disturbances in the Prodromal Stage of Parkinson Disease.
    Al-Qassabi A; Fereshtehnejad SM; Postuma RB
    Curr Treat Options Neurol; 2017 Jun; 19(6):22. PubMed ID: 28466429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Dual-Task Walking Paradigms to Detect Prodromal Parkinson's and Alzheimer's Diseases.
    Belghali M; Chastan N; Davenne D; Decker LM
    Front Neurol; 2017; 8():207. PubMed ID: 28588547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges.
    Kim D; Kim YS; Shin DW; Park CS; Kang JH
    J Clin Neurol; 2016 Oct; 12(4):381-392. PubMed ID: 27819412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis.
    Donaghy PC; McKeith IG
    Alzheimers Res Ther; 2014; 6(4):46. PubMed ID: 25484925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.